The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer.

Abstract:

BACKGROUND:The aromatase inhibitors (AIs) are increasingly surpassing tamoxifen as the endocrine treatment of choice for postmenopausal breast cancer patients. With their increasing use, there is concern that they are being inadvertently prescribed to pre- and peri-menopausal women. METHODS:As part of a continuing medical education program for 264 practicing surgeons, a 15-min lecture was given over viewing hormone therapy for early stage breast cancer. Two multi-choice questions were asked before and after the lecture regarding the optimal hormonal treatment for pre and postmenopausal women. RESULTS:For the optimal treatment of premenopausal women, 36% of respondents chose tamoxifen before the lecture, rising to 82% after it (p<0.01). However 37% suggested an AI would be best, with a further 27% choosing either an AI or tamoxifen, falling to 7% and 11% respectively after the lecture. Before the lecture, 30% of the participants stated that any of the listed treatment options; tamoxifen alone, an AI alone or a combination of tamoxifen and an AI would be acceptable for postmenopausal women. Following the lecture, 53% chose this option (p<0.01). CONCLUSIONS:In many countries it is practicing surgeons who commence endocrine therapy for patients with breast cancer. The findings of this study are useful from two points. Firstly it is clear that many physicians feel that AIs are an effective adjuvant endocrine therapy for premenopausal breast cancer. Secondly it demonstrates the benefits of continuing medical education as a significant improvement in test scores was noted after a structured lecture.

authors

Gainford MC,McCready D,Clemons M

doi

10.1007/s10549-005-9031-9

subject

Has Abstract

pub_date

2006-04-01 00:00:00

pages

203-6

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

96

pub_type

杂志文章
  • A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.

    abstract::ALIQUOT (Anastrozole vs. Letrozole, an Investigation of Quality Of Life and Tolerability) was a prospective, open-label, randomized pharmacodynamic study designed to assess the effects of aromatase inhibitors (AIs) on bone turnover in healthy postmenopausal women with estrogen receptor-positive breast cancer. Ninety-f...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-009-0646-0

    authors: McCaig FM,Renshaw L,Williams L,Young O,Murray J,Macaskill EJ,McHugh M,Hannon R,Dixon JM

    更新日期:2010-02-01 00:00:00

  • XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects.

    abstract::Published data on the association between Xeroderma Pigmentosum complementation group D (XPD) Lys751Gln polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association be...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-010-0813-3

    authors: Qiu LX,Yao L,Zhang J,Zhu XD,Zhao XM,Xue K,Mao C,Chen B,Zhan P,Yuan H,Hu XC

    更新日期:2010-11-01 00:00:00

  • Microsatellite genotyping reveals a signature in breast cancer exomes.

    abstract::Genomic instability at microsatellite loci is a hallmark of many cancers, including breast cancer. However, much of the genomic variation and many of the hereditary components responsible for breast cancer remain undetected. We hypothesized that variation at microsatellites could provide additional genomic markers for...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2908-8

    authors: McIver LJ,Fonville NC,Karunasena E,Garner HR

    更新日期:2014-06-01 00:00:00

  • Ras-related protein 1 and the insulin-like growth factor type I receptor are associated with risk of progression in patients diagnosed with carcinoma in situ.

    abstract::Currently, there are no applied molecular markers to aid in predicting risk of carcinoma in situ (CIS) progression to invasive cancer, and therefore, all women diagnosed with CIS undergo surgery. Standard assessment of protein expression in fixed tissue by immunohistochemistry (IHC) is not quantitative and hence is no...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1227-y

    authors: Furstenau DK,Mitra N,Wan F,Lewis R,Feldman MD,Fraker DL,Guvakova MA

    更新日期:2011-09-01 00:00:00

  • Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.

    abstract::The aim of this study was to evaluate the difference in outcomes based on p53 overexpression of patients with breast cancer who received adjuvant therapy following local treatment for invasive ductal carcinoma, not otherwise specified. We analyzed data from 4,683 patients with cancer enrolled in two institutions betwe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-009-0560-5

    authors: Kim HS,Yom CK,Kim HJ,Lee JW,Sohn JH,Kim JH,Park YL,Ahn SH

    更新日期:2010-06-01 00:00:00

  • Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells.

    abstract::Estrogen receptor beta (ERbeta) is widely expressed in mammary epithelium. ERbeta expression is reported to decline during carcinogenesis of the breast and other tissues. In this study, we examined the consequences of a loss of ERbeta expression in mammary epithelial cells. We knocked down ERbeta transcript levels in ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0413-2

    authors: Treeck O,Lattrich C,Springwald A,Ortmann O

    更新日期:2010-04-01 00:00:00

  • Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.

    abstract:PURPOSE:This study aimed to identify and classify genetic variants in consensus moderate-to-high-risk predisposition genes associated with Hereditary Breast and Ovarian Cancer Syndrome (HBOC), in BRCA1/2-negative patients from Brazil. METHODS:The study comprised 126 index patients who met NCCN clinical criteria and te...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05985-9

    authors: Gomes R,Spinola PDS,Brant AC,Matta BP,Nascimento CM,de Aquino Paes SM,Bonvicino CR,Dos Santos ACE,Moreira MAM

    更新日期:2020-10-30 00:00:00

  • Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines.

    abstract::The regulation of gene expression by steroid hormones plays an important role in the normal development and function of many organs, as well in the pathogenesis of endocrine-related cancers. Previous experiments have shown that many kallikrein genes are under steroid hormone regulation in breast cancer cell lines. We ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9312-y

    authors: Paliouras M,Diamandis EP

    更新日期:2007-03-01 00:00:00

  • Flexible covariate effects in the proportional hazards model.

    abstract::The proportional hazards model is frequently used in analyzing the results of clinical trials, when it is often the case that the outcomes are right-censored. This model allows one to measure treatment effects and simultaneously identify and adjust for prognostic factors that might influence the outcome. In this paper...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF01840837

    authors: Hastie T,Sleeper L,Tibshirani R

    更新日期:1992-01-01 00:00:00

  • Diagnostic ability of different human milk fat globule antigens in breast cancer.

    abstract::Human mammary epithelial antigens (HME-Ags) are released into the circulation by breast tumors and not by normal breast tissue (Proc. Natl. Acad. Sci. USA 74: 582-586, 1977). This characteristic made them valuable, together with other breast cancer related antigens later identified, to develop immunoassays useful in t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806353

    authors: Ceriani RL,Blank EW,Rosenbaum EH,Ben Zeev D,Lowitz RS,Johansen L,Trujillo T

    更新日期:1990-05-01 00:00:00

  • Sphingosine-1-phosphate, a novel second messenger involved in cell growth regulation and signal transduction, affects growth and invasiveness of human breast cancer cells.

    abstract::This review will focus on the role of sphingosine and its phosphorylated derivative sphingosine-1-phosphate (SPP) in cell growth regulation and signal transduction. We will show that many of the effects attributed to sphingosine in quiescent Swiss 3T3 fibroblasts are mediated via its conversion to SPP. We propose that...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00666166

    authors: Spiegel S,Olivera A,Zhang H,Thompson EW,Su Y,Berger A

    更新日期:1994-01-01 00:00:00

  • Women with breast cancer report substantially more disease- and treatment-related side or late effects than registered by clinical oncologists: a cross-sectional study of a standard follow-up program in an oncological department.

    abstract:BACKGROUND:Follow-up after breast cancer treatment is standard due to the risk of development of new primary cancers and recurrent disease. The aim of the present study was to evaluate a standard follow-up program in an oncological department by assessing: (1) Symptoms or signs of new primary cancer or recurrent diseas...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4301-x

    authors: Ellegaard MB,Grau C,Zachariae R,Jensen AB

    更新日期:2017-08-01 00:00:00

  • Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage.

    abstract::The biological and clinical significance of circulating tumor cells (CTC) in the peripheral blood of breast cancer patients is not known. To study this question, we used a direct visualization assay to correlate the number of CTC with disease stage and progression. The CTC were enriched from the nucleated cell fractio...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000036897.92513.72

    authors: Kahn HJ,Presta A,Yang LY,Blondal J,Trudeau M,Lickley L,Holloway C,McCready DR,Maclean D,Marks A

    更新日期:2004-08-01 00:00:00

  • Bulky DNA adducts and breast cancer risk in the prospective EPIC-Italy study.

    abstract::The role of environmental carcinogen exposure in breast cancer development has long been suspected, but no specific association has been identified so far. A few molecular epidemiology studies reported that DNA adducts detected by different methods are associated with a modest increase of breast cancer risk. We aimed ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1472-8

    authors: Saieva C,Peluso M,Masala G,Munnia A,Ceroti M,Piro S,Sera F,Bendinelli B,Pala V,Sieri S,Tumino R,Giurdanella MC,Panico S,Mattiello A,Vineis P,Polidoro S,Matullo G,Palli D

    更新日期:2011-09-01 00:00:00

  • Racial differences in employment and cost-management behaviors in patients with metastatic breast cancer.

    abstract:PURPOSE:Little is known about racial variations in the financial impact of cancer care. Using data from a national survey of racially diverse patients with metastatic breast cancer, we examined racial/ethnic patterns in employment and cost-management (i.e., financial coping) behaviors. METHODS:We conducted an online s...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05449-9

    authors: Samuel CA,Spencer JC,Rosenstein DL,Reeder-Hayes KE,Manning ML,Sellers JB,Wheeler SB

    更新日期:2020-01-01 00:00:00

  • PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.

    abstract:PURPOSE:To determine if response to endocrine therapy of breast cancer can be predicted by either a metabolic "flare reaction" detected by positron emission tomography (PET) with 2-[(18)F]-fluoro-2-deoxyglucose (FDG), induced by an estradiol challenge, or by estrogen-receptor (ER) status, determined by PET with the est...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-9953-0

    authors: Dehdashti F,Mortimer JE,Trinkaus K,Naughton MJ,Ellis M,Katzenellenbogen JA,Welch MJ,Siegel BA

    更新日期:2009-02-01 00:00:00

  • Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.

    abstract:BACKGROUND:Women affected with breast cancer who carry a BRCA1 or BRCA2 (BRCA1/2) mutation are at risk of developing contralateral breast cancer. To reduce the risk of contralateral breast cancer, some patients opt for prophylactic surgery of the unaffected breast (contralateral prophylactic mastectomy, CPM) in additio...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9423-5

    authors: Graves KD,Peshkin BN,Halbert CH,DeMarco TA,Isaacs C,Schwartz MD

    更新日期:2007-09-01 00:00:00

  • Carotenoids and breast cancer risk: a meta-analysis and meta-regression.

    abstract::The purpose of this article is to comprehensively summarize the associations between carotenoids and breast cancer and quantitatively estimate their dose-response relationships. We searched PubMed, Embase, and Cochrane databases (from January 1982 to 1 May 2011) and the references of the relevant articles in English w...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-011-1723-8

    authors: Hu F,Wang Yi B,Zhang W,Liang J,Lin C,Li D,Wang F,Pang D,Zhao Y

    更新日期:2012-01-01 00:00:00

  • Analysis of the breast cancer methylome using formalin-fixed paraffin-embedded tumour.

    abstract:PURPOSE:Aberrant DNA methylation occurs frequently in breast carcinogenesis. Tools for translational epigenetic studies of breast cancer involving formalin-fixed paraffin-embedded (FFPE) human tissues have now been developed. Few studies have measured genome-wide methylation in DNA derived from paraffin-embedded tumour...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3971-0

    authors: Wong EM,Joo JE,McLean CA,Baglietto L,English DR,Severi G,Wu HC,Terry MB,Hopper JL,Milne RL,Giles GG,Southey MC

    更新日期:2016-11-01 00:00:00

  • One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).

    abstract::Genetic testing enables women at risk for hereditary breast and/or ovarian cancer to find out whether they have inherited the gene mutation (BRCA1/BRCA2), and if so, to opt for frequent surveillance and/or prophylactic surgery (bilateral mastectomy and/or oophorectomy). Here, a follow-up is described for 63 healthy wo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1015269620265

    authors: Lodder LN,Frets PG,Trijsburg RW,Meijers-Heijboer EJ,Klijn JG,Seynaeve C,van Geel AN,Tilanus MM,Bartels CC,Verhoog LC,Brekelmans CT,Burger CW,Niermeijer MF

    更新日期:2002-05-01 00:00:00

  • BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research.

    abstract::The Breast Cancer Family Registry is a resource for interdisciplinary and translational studies of the genetic epidemiology of breast cancer. This resource is available to researchers worldwide for collaborative studies. Herein, we report the results of testing for germline mutations in BRCA1 and BRCA2. We have tested...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0153-8

    authors: Neuhausen SL,Ozcelik H,Southey MC,John EM,Godwin AK,Chung W,Iriondo-Perez J,Miron A,Santella RM,Whittemore A,Andrulis IL,Buys SS,Daly MB,Hopper JL,Seminara D,Senie RT,Terry MB,Breast Cancer Family Registry.

    更新日期:2009-07-01 00:00:00

  • Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells.

    abstract:PURPOSE:Elevated expression of PAI-1 has been widely linked with adverse outcomes in a variety of human cancers, such as breast, gastric and ovarian cancers, rendering PAI-1 a prognostic biomarker. As a result, several chemical inhibitors are currently being developed against PAI-1; however, the clinical setting where ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-06054-x

    authors: Tzekaki EE,Geromichalos G,Lavrentiadou SN,Tsantarliotou MP,Pantazaki AA,Papaspyropoulos A

    更新日期:2021-01-03 00:00:00

  • The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.

    abstract::Platinum agents such as cisplatin and carboplatin are DNA-damaging agents with activity in breast cancer (BC), particularly in the triple negative (TN) subgroup. The utility of platinum agents, in addition to standard neoadjuvant chemotherapy (NAC), is controversial. To assess the activity of platinum agents in patien...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-014-2876-z

    authors: Petrelli F,Coinu A,Borgonovo K,Cabiddu M,Ghilardi M,Lonati V,Barni S

    更新日期:2014-04-01 00:00:00

  • Prolactin levels and molecular heterogeneity in rat strains with high and low incidence of DMBA-induced mammary tumors.

    abstract::We compared the following parameters in Long-Evans (LE) and Sprague-Dawley (SD) female rats: 1) mammary tumor incidence after DMBA, 2) plasma prolactin (PRL) during the estrous cycle before and after DMBA, 3) plasma PRL in immature females from 0900 hr on day 29 to 0900 hr on day 30, 4) plasma PRL from 1200 to 1700 hr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806395

    authors: Lawson DM,Sensui N,Haisenleder DH,Kaufman PN,Gala RR

    更新日期:1984-01-01 00:00:00

  • International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases.

    abstract::Recently, many centers have omitted routine axillary lymph node dissection (ALND) after metastatic sentinel node biopsy in breast cancer due to a growing body of literature. However, existing guidelines of adjuvant treatment planning are strongly based on axillary nodal stage. In this study, we aim to develop a novel ...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s10549-013-2468-3

    authors: Meretoja TJ,Audisio RA,Heikkilä PS,Bori R,Sejben I,Regitnig P,Luschin-Ebengreuth G,Zgajnar J,Perhavec A,Gazic B,Lázár G,Takács T,Kővári B,Saidan ZA,Nadeem RM,Castellano I,Sapino A,Bianchi S,Vezzosi V,Barranger E,L

    更新日期:2013-04-01 00:00:00

  • Four cases of chylous fistula after breast cancer resection.

    abstract::Chylous fistulas in cases treated surgically for breast cancer only, are rare. We encountered four chylous fistula cases after breast cancer operations out of a total of 851 cases, all of which involved the left breast. Chylous fistulas were confirmed by axillary white fluid and were unrelated to obesity, surgical met...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000010675.87358.b6

    authors: Nakajima E,Iwata H,Iwase T,Murai H,Mizutani M,Miura S,Kato H

    更新日期:2004-01-01 00:00:00

  • Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy.

    abstract:PURPOSE:The selective treatment of internal mammary lymph nodes (IMNs) in breast cancer is controversial. The purpose of this research was to determine the subpopulation patients with high risk of internal mammary lymph nodes metastasis who received extended radical mastectomy without any preoperative treatment from 19...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9561-4

    authors: Huang O,Wang L,Shen K,Lin H,Hu Z,Liu G,Wu J,Lu J,Shao Z,Han Q,Shen Z

    更新日期:2008-02-01 00:00:00

  • PALB2 mutations in German and Russian patients with bilateral breast cancer.

    abstract::Since germline mutations in the PALB2 (Partner and Localizer of BRCA2) gene have been identified as breast cancer (BC) susceptibility alleles, the geographical spread and risks associated with PALB2 mutations are subject of intense investigation. Patients with bilateral breast cancer constitute a valuable group for ge...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1290-4

    authors: Bogdanova N,Sokolenko AP,Iyevleva AG,Abysheva SN,Blaut M,Bremer M,Christiansen H,Rave-Fränk M,Dörk T,Imyanitov EN

    更新日期:2011-04-01 00:00:00

  • PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation.

    abstract:PURPOSE:Radiotherapy (RT) constitutes an important part of breast cancer treatment. However, triple negative breast cancers (TNBC) exhibit remarkable resistance to most therapies, including RT. Developing new ways to radiosensitize TNBC cells could result in improved patient outcomes. The M2 isoform of pyruvate kinase ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05376-9

    authors: Zhang L,Bailleul J,Yazal T,Dong K,Sung D,Dao A,Gosa L,Nathanson D,Bhat K,Duhachek-Muggy S,Alli C,Dratver MB,Pajonk F,Vlashi E

    更新日期:2019-11-01 00:00:00

  • CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

    abstract:PURPOSE:A number of studies have tested the hypothesis that breast cancer patients with low-activity CYP2D6 genotypes achieve inferior benefit from tamoxifen treatment, putatively due to lack of metabolic activation to endoxifen. Studies have provided conflicting data, and meta-analyses suggest a small but significant ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4400-8

    authors: Hertz DL,Kidwell KM,Hilsenbeck SG,Oesterreich S,Osborne CK,Philips S,Chenault C,Hartmaier RJ,Skaar TC,Sikora MJ,Rae JM

    更新日期:2017-11-01 00:00:00